OC
BMY.RT

Oppenheimer & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Oppenheimer & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-43,424
Closed -$30K – 1532
2020
Q4 		$30K Buy
43,424
+630
+1% +$1.34K ﹤0.01% 1333
2020
Q3 		$97K Sell
42,794
-4,157
-9% -$11.9K ﹤0.01% 1233
2020
Q2 		$168K Sell
46,951
-2,019
-4% -$7.28K ﹤0.01% 1147
2020
Q1 		$186K Sell
48,970
-4,913
-9% -$16.2K 0.01% 1045
2019
Q4 		$162K Buy
+53,883
New +$140K ﹤0.01% 1205

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Oppenheimer & Co's BMY.RT Position: Q1 2021 in Review

Oppenheimer & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 43,424 shares — an estimated $30K sold.

Oppenheimer & Co first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $186K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Oppenheimer & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 43,424 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $30K.
  • Oppenheimer & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Oppenheimer & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $186K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Oppenheimer & Co's 13F filing for Q1 2021, filed 10 May 2021.